A small molecule targeting the protein-protein interaction between a chromatin binding protein and an oncogenic transcription factor shows therapeutic potential in a subtype of acute myeloid leukemia.
This is a preview of subscription content, access via your institution
Access options
References
Dharmarajan, V., Lee, J.H., Patel, A., Skalnik, D.G. & Cosgrove, M.S. J. Biol. Chem. 287, 27275–27289 (2012).
Zhang, P., Lee, H., Brunzelle, J.S. & Couture, J.F. Nucleic Acids Res. 40, 4237–4246 (2012).
McGrath, J. & Trojer, P. Pharmacol. Ther. 150, 1–22 (2015).
Grebien, F. et al. Nat. Chem. Biol. 10.1038/nchembio.1859 (13 July 2015).
Bolshan, Y. et al. ACS Med. Chem. Lett. 4, 353–357 (2013).
Senisterra, G. et al. Biochem. J. 449, 151–159 (2013).
Cao, F. et al. Mol. Cell 53, 247–261 (2014).
Dias, J. et al. Genes Dev. 28, 929–942 (2014).
Thomas, L.R. et al. Mol. Cell 58, 440–452 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Trojer, P. Disrupting histone lysine methylation. Nat Chem Biol 11, 552–554 (2015). https://doi.org/10.1038/nchembio.1861
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1861